Maker of Experimental ‘ZMapp’ Ebola Drug Says Supply Is Exhausted
Mapp Biopharmaceutical Provided Doses to an African Nation
By Peter Loftus
Aug. 12, 2014
The maker of the experimental Ebola drug that was given to two infected Americans said Monday that its supply has been exhausted after the company provided doses to a West African nation.
Mapp Biopharmaceutical Inc. said in a brief online statement it had complied with every request for the drug that had the necessary legal and regulatory authorization. The company said it provided the drug, called ZMapp, at no cost in all cases.
San Diego-based Mapp didn’t name any countries that requested the drug and didn’t release additional details.
In a statement Monday, the office of Liberia’s president said the U.S. planned to deliver sample doses of an “experimental serum” to Liberia later this week to treat Liberian doctors infected with Ebola.
Liberia said the shipment was in response to a request Friday sent to President Obama by Liberian President Ellen Johnson Sirleaf. The statement didn’t name the drug.